Figure 3
From: Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia
A 5hmC signature predicts overall survival in AML patients. (a) Kaplan–Meier analysis of overall survival of AML patients in training set based on wp-scores (n = 50). (b) Kaplan–Meier analysis of overall survival of AML patients in validation set based on wp-scores (n = 26). (c) Overall survival analysis of 61 AML patients with cytogenetic and/or molecular genetic information following the European LeukemiaNet (ELN) risk classification. (d) Association of wp-score with risk stratification of the 61 AML patients categorized using ELN classification. Favorable, n = 7; Intermediate, n = 33; Adverse, n = 21. Black dashed line represents a cutoff wp-score of 18.0 developed from training set. Center line represents median, bounds of box represent 25th and 75th percentiles, and whiskers are Tukey whiskers. (e) Overall survival analysis of the 61 AML patients with cytogenetic and/or molecular information available based on wp-scores. (f) Wp-score further stratifies patients in the intermediate group (n = 33) categorized by ELN recommendations.
